Company Overview
About Evozyne
Evozyne is a Chicago-based biotechnology company founded in 2020 by Andrew Ferguson and Rama Ranganathan that uses generative AI to design novel, high-performance proteins for therapeutic and commercial applications. The company occupies a distinctive position at the frontier of AI-driven drug discovery: unlike companies that apply AI to screen existing molecule libraries or predict protein folding (like AlphaFold), Evozyne generates entirely new protein sequences from scratch using its proprietary understanding of evolutionary sequence-function relationships. These de novo proteins are designed with specific functional properties for therapeutic development or industrial applications.
Business Model & Competitive Advantage
Evozyne has raised $144M in total funding across four rounds. Its $81M Series B was led by Fidelity Management & Research Company and OrbiMed, with participation from NVentures (NVIDIA''s venture arm) — a significant endorsement given NVIDIA''s central role in AI computing infrastructure. The company has approximately 54 employees and is led by CEO Marc Yoskowitz, who joined from Tempus AI. Evozyne''s platform combines machine learning models trained on evolutionary protein sequence data with high-throughput gene synthesis and laboratory screening to iteratively design and validate protein candidates.
Competitive Landscape 2025–2026
Evozyne''s primary focus areas include therapeutic protein design — targeting diseases where novel protein biologics could offer better efficacy or tolerability than existing treatments — and environmental sustainability applications such as designing enzymes for industrial processes. The company is one of a small cohort of AI-native biotechs advancing de novo therapeutic proteins toward clinical evaluation. It competes with Profluent, Generate Biomedicines, and David Baker''s laboratory spinouts, as well as larger AI drug discovery players like Recursion Pharmaceuticals and Insilico Medicine, though Evozyne''s generative protein design approach is more foundational than conventional AI-for-drug-discovery methods.
Key Differentiators
Emerging Innovator
Evozyne is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Compare Evozyne with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Evozyne? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Evozyne Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Evozyne vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →